Incisive Genetics
Dr. Michael Hayden MBChB , PhD - Chief Executive Officer - Prilenia | LinkedIn
Michael Hayden, MD PhD | CMHF
The Difficulties of Cloning a CEO - Bloomberg
ABOUT US | Prilenia Therapeutics
Dr. Michael Hayden MBChB , PhD - Chief Executive Officer - Prilenia | LinkedIn
Michael Hayden, MD, PhD - World Neuroscience Innovation Forum
How One of the World's Leading Geneticists Recovered His Family's Stolen Legacy - Tablet Magazine
At Risk for Huntington's Disease: 'Darkness replaced by hope and light': taking stock of Huntington's disease research
Podcast Transcript Michael Hayden and PROOF-HD v.1 08Jan2021
How One of the World's Leading Geneticists Recovered His Family's Stolen Legacy - Tablet Magazine
Troubled Drugmaker Teva to Axe over 4,000 Jobs | Ctech
Axovant poaches Allergan's and Teva's chief medical and science officers - PMLiVE
Michael Hayden, MD PhD | CMHF
Michal GEVA | Associate Director, Project Leader | PhD | Teva Pharmaceutical Industries Ltd., Petah Tikva | TEVA | Pharmacology | Research profile
Teva appoints genetics specialist as its first president of global R&D - PMLiVE
Michael Hayden - Director at n-Lorem Foundation | The Org
New Teva CEO axes R&D chief Hayden in boardroom shakeup – gr-cis.com
Michael Hayden, MD PhD | CMHF
Meet the Investigator – HD Insights
Prilenia Therapeutics raises $62.5m, names Michael Hayden CEO - Globes
Michael Hayden, MD PhD | CMHF
New Teva CEO shakes up structure and leadership at troubled drugmaker | The Times of Israel
Israel Ministry of Foreign Affairs - Premier Kathleen Wynne visited Teva Pharmaceutical Industries Ltd., where she met with Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer. Israeli Teva is
Former Teva Executives Raise $60 Million for Metabolic Disorders Venture | Ctech
Teva to Cut Up to 25% of Israel Workforce, Calcalist Says - Bloomberg
Michael Hayden - News, Articles, Whitepapers - Drug Target Review
